SBI Securities Co. Ltd. Purchases New Shares in Achieve Life Sciences, Inc. (NASDAQ:ACHV)

SBI Securities Co. Ltd. acquired a new position in Achieve Life Sciences, Inc. (NASDAQ:ACHV) in the fourth quarter, according to the company in its most recent filing with the Securities & Exchange Commission. The institutional investor acquired 14,023 shares of the biopharmaceutical company’s stock, valued at approximately $49,000.

Other hedge funds have also modified their holdings of the company. Barclays PLC increased its stake in Achieve Life Sciences by 303.1% during the 3rd quarter. Barclays PLC now owns 47,655 shares of the biopharmaceutical company’s stock worth $226,000 after buying an additional 35,832 shares in the last quarter. Geode Capital Management LLC boosted its stake in shares of Achieve Life Sciences by 6.9% in the third quarter. Geode Capital Management LLC now owns 749,109 shares of the biopharmaceutical company’s stock worth $3,552,000 after acquiring an additional 48,474 shares during the last quarter. State Street Corp increased its position in shares of Achieve Life Sciences by 6.8% during the third quarter. State Street Corp now owns 431,520 shares of the biopharmaceutical company’s stock worth $2,045,000 after purchasing an additional 27,419 shares in the last quarter. SG Americas Securities LLC raised its stake in Achieve Life Sciences by 74.8% in the 4th quarter. SG Americas Securities LLC now owns 19,886 shares of the biopharmaceutical company’s stock valued at $70,000 after purchasing an additional 8,512 shares during the last quarter. Finally, MetLife Investment Management LLC raised its stake in Achieve Life Sciences by 65.6% in the 3rd quarter. MetLife Investment Management LLC now owns 14,993 shares of the biopharmaceutical company’s stock valued at $71,000 after purchasing an additional 5,939 shares during the last quarter. 33.52% of the stock is owned by hedge funds and other institutional investors.

Wall Street Analyst Weigh In

A number of research firms have commented on ACHV. RODMAN&RENSHAW upgraded shares of Achieve Life Sciences to a “strong-buy” rating in a report on Thursday, November 14th. Rodman & Renshaw began coverage on Achieve Life Sciences in a research report on Thursday, November 14th. They issued a “buy” rating and a $12.00 price target for the company. Three analysts have rated the stock with a buy rating and two have issued a strong buy rating to the company. According to data from MarketBeat, the company has an average rating of “Buy” and an average price target of $15.75.

Achieve Life Sciences Price Performance

Shares of ACHV opened at $3.06 on Tuesday. The company has a debt-to-equity ratio of 0.31, a current ratio of 6.78 and a quick ratio of 6.78. Achieve Life Sciences, Inc. has a 1-year low of $2.82 and a 1-year high of $5.59. The stock has a market cap of $105.23 million, a PE ratio of -2.71 and a beta of 1.67. The firm has a fifty day moving average price of $3.23 and a 200 day moving average price of $4.06.

Achieve Life Sciences Company Profile

Achieve Life Sciences, Inc, a clinical-stage pharmaceutical company, develops and commercializes cytisinicline for smoking cessation and nicotine addiction. The company offers cytisinicline, a plant-based alkaloid that interacts with nicotine receptors in the brain that reduce the severity of nicotine withdrawal symptoms.